Gilead Sciences Doubles Its Profit To $12.1 Billion On Strength Of $1,000 Per Pill Hepatitis Drug
A Bay Area pharmaceutical firm is among other top drug makers facing scrutiny over enormous profits, the price charged for drugs, and how much the company spends on marketing versus research and development.